ClinicalTrials.gg
TerminatedNCT00134264ILLUMINATEUpdated Feb 3, 2012

A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease

A Phase 3 interventional study of torcetrapib/atorvastatin and atorvastatin in Coronary Disease and Diabetes Mellitus, sponsored by Pfizer. Terminated at 221 sites in 7 countries. Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-02-03.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
15,067
Allocation
Randomized
Ages
45 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 11 studies testing atorvastatin in Coronary Disease — none open to participants now, none under way, none of them phase 3. Atorvastatin · Coronary Disease.

Enrollment
Largest of 10
15,067 · median 200
Started
2004
the only one that year
Phase 3
2 of 11
none open now
Registered
1st of 11
by date
Lead sponsor
3 of 11
Pfizer

Among the 11 studies testing atorvastatin in Coronary Disease, this one has the largest enrollment of the 10 interventional ones that give a count, is the only one that started in 2004, is one of 2 in phase 3, and was the 1st registered.

Coronary Disease

1,521 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

None of the 11 studies testing atorvastatin in Coronary Disease is open now. The open studies under Coronary Disease, anywhere →

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 105 Coronary Disease studies recruiting now, 63 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 45 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing atorvastatin in Coronary Disease as a file.
02

Study summary

The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

To demonstrate if torcetrapib/atorvastatin can reduce the risk for major cardiovascular disease events, when compared to atorvastatin alone, in patients with coronary heart disease or risk equivalents

03

Conditions studied

  • Coronary Disease
  • Diabetes Mellitus
04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of coronary heart disease or risk equivalents that place the patient at high risk for cardiovascular disease events

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or lactating, or planning to become pregnant.
  • Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid
  • Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
  • Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluationof response, or render unlikely that the subject would complete the study
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
15,067 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. The time to first occurrence of a major cardiovascular disease event

Secondary outcomes

  1. Various composites of major cardiovascular disease events and other lipid parameters

07

Study locations

221 sites
  • Pfizer Investigational Site
    Alabaster, Alabama, United States
  • Pfizer Investigational Site
    Birmingham, Alabama, United States
  • Pfizer Investigational Site
    Gilbert, Arizona, United States
  • Pfizer Investigational Site
    Phoenix, Arizona, United States
  • Pfizer Investigational Site
    Tucson, Arizona, United States
  • Pfizer Investigational Site
    Fresno, California, United States
  • Pfizer Investigational Site
    Los Angeles, California, United States
  • Pfizer Investigational Site
    Modesto, California, United States
  • Pfizer Investigational Site
    San Diego, California, United States
  • Pfizer Investigational Site
    Santa Rosa, California, United States
  • Pfizer Investigational Site
    Tustin, California, United States
  • Pfizer Investigational Site
    Walnut Creek, California, United States
  • Pfizer Investigational Site
    Denver, Colorado, United States
  • Pfizer Investigational Site
    Longmont, Colorado, United States
  • Pfizer Investigational Site
    Guilford, Connecticut, United States
  • Pfizer Investigational Site
    Hartford, Connecticut, United States
  • Pfizer Investigational Site
    Washington, District of Columbia, United States
  • Pfizer Investigational Site
    Clearwater, Florida, United States
  • Pfizer Investigational Site
    Coral Gables, Florida, United States
  • Pfizer Investigational Site
    Fort Meyers, Florida, United States
  • Pfizer Investigational Site
    Jacksonville Beach, Florida, United States
  • Pfizer Investigational Site
    Jacksonville, Florida, United States
  • Pfizer Investigational Site
    Lakeland, Florida, United States
  • Pfizer Investigational Site
    Orlando, Florida, United States
  • Pfizer Investigational Site
    Pensacola, Florida, United States
  • Pfizer Investigational Site
    Port Charlotte, Florida, United States
  • Pfizer Investigational Site
    Sarasota, Florida, United States
  • Pfizer Investigational Site
    West Palm Beach, Florida, United States
  • Pfizer Investigational Site
    Atlanta, Georgia, United States
  • Pfizer Investigational Site
    Aurora, Illinois, United States
  • Pfizer Investigational Site
    Blue Island, Illinois, United States
  • Pfizer Investigational Site
    Chicago, Illinois, United States
  • Pfizer Investigational Site
    Evansville, Indiana, United States
  • Pfizer Investigational Site
    Fort Wayne, Indiana, United States
  • Pfizer Investigational Site
    Davenport, Iowa, United States
  • Pfizer Investigational Site
    des Moines, Iowa, United States
  • Pfizer Investigational Site
    Iowa City, Iowa, United States
  • Pfizer Investigational Site
    Wichita, Kansas, United States
  • Pfizer Investigational Site
    Witchita, Kansas, United States
  • Pfizer Investigational Site
    Louisville, Kentucky, United States
  • Pfizer Investigational Site
    Baton Rouge, Louisiana, United States
  • Pfizer Investigational Site
    Covington, Louisiana, United States
  • Pfizer Investigational Site
    Marrero, Louisiana, United States
  • Pfizer Investigational Site
    Scarborough, Maine, United States
  • Pfizer Investigational Site
    Baltimore, Maryland, United States
  • Pfizer Investigational Site
    Bel Air, Maryland, United States
  • Pfizer Investigational Site
    Columbia, Maryland, United States
  • Pfizer Investigational Site
    Towson, Maryland, United States
  • Pfizer Investigational Site
    Westminster, Maryland, United States
  • Pfizer Investigational Site
    Abington, Massachusetts, United States
  • Pfizer Investigational Site
    Haverhill, Massachusetts, United States
  • Pfizer Investigational Site
    Natick, Massachusetts, United States
  • Pfizer Investigational Site
    Grand Rapids, Michigan, United States
  • Pfizer Investigational Site
    Minneapolis, Minnesota, United States
  • Pfizer Investigational Site
    St. Paul, Minnesota, United States
  • Pfizer Investigational Site
    St. Louis, Missouri, United States
  • Pfizer Investigational Site
    Billings, Montana, United States
  • Pfizer Investigational Site
    Butte, Montana, United States
  • Pfizer Investigational Site
    Omaha, Nebraska, United States
  • Pfizer Investigational Site
    Papillon, Nebraska, United States
  • Pfizer Investigational Site
    Las Vegas, Nevada, United States
  • Pfizer Investigational Site
    Concord, New Hampshire, United States
  • Pfizer Investigational Site
    Lebanon, New Hampshire, United States
  • Pfizer Investigational Site
    Manchester, New Hampshire, United States
  • Pfizer Investigational Site
    Elmer, New Jersey, United States
  • Pfizer Investigational Site
    Haddon Heights, New Jersey, United States
  • Pfizer Investigational Site
    New Brunswick, New Jersey, United States
  • Pfizer Investigational Site
    Garden City, New York, United States
  • Pfizer Investigational Site
    New Hyde Park, New York, United States
  • Pfizer Investigational Site
    Rochester, New York, United States
  • Pfizer Investigational Site
    Durham, North Carolina, United States
  • Pfizer Investigational Site
    Winston-salem, North Carolina, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio, United States
  • Pfizer Investigational Site
    Cleveland, Ohio, United States
  • Pfizer Investigational Site
    Columbus, Ohio, United States
  • Pfizer Investigational Site
    Mansfield, Ohio, United States
  • Pfizer Investigational Site
    Sandusky, Ohio, United States
  • Pfizer Investigational Site
    Toledo, Ohio, United States
  • Pfizer Investigational Site
    Oklahoma City, Oklahoma, United States
  • Pfizer Investigational Site
    Portland, Oregon, United States
  • Pfizer Investigational Site
    Beaver, Pennsylvania, United States
  • Pfizer Investigational Site
    Philadelphia, Pennsylvania, United States
  • Pfizer Investigational Site
    Kingsport, Tennessee, United States
  • Pfizer Investigational Site
    Nashville, Tennessee, United States
  • Pfizer Investigational Site
    Beaumont, Texas, United States
  • Pfizer Investigational Site
    Dallas, Texas, United States
  • Pfizer Investigational Site
    Houston, Texas, United States
  • Pfizer Investigational Site
    Plano, Texas, United States
  • Pfizer Investigational Site
    San Antonio, Texas, United States
  • Pfizer Investigational Site
    Salt Lake City, Utah, United States
  • Pfizer Investigational Site
    Burlington, Vermont, United States
  • Pfizer Investigational Site
    Norfolk, Virginia, United States
  • Pfizer Investigational Site
    Richmond, Virginia, United States
  • Pfizer Investigational Site
    Burien, Washington, United States
  • Pfizer Investigational Site
    Tacoma, Washington, United States
  • Pfizer Investigational Site
    Concord, New South Wales, Australia
  • Pfizer Investigational Site
    East Gosford, New South Wales, Australia
  • Pfizer Investigational Site
    St. Leonards, New South Wales, Australia
  • Pfizer Investigational Site
    Wollongong, New South Wales, Australia
  • Pfizer Investigational Site
    Chermside, Queensland, Australia

Showing the first 100 of 221 sites across 7 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Arsenault BJ, Petrides F, Tabet F, Bao W, Hovingh GK, Boekholdt SM, Ramin-Mangata S, Meilhac O, DeMicco D, Rye KA, Waters DD, Kastelein JJP, Barter P, Lambert G. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. J Clin Lipidol. 2018 Jan-Feb;12(1):130-136. doi: 10.1016/j.jacl.2017.10.001. Epub 2017 Oct 12. PubMed 29103916 ↗
  • Williams SA, Murthy AC, DeLisle RK, Hyde C, Malarstig A, Ostroff R, Weiss SJ, Segal MR, Ganz P. Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib. Circulation. 2018 Mar 6;137(10):999-1010. doi: 10.1161/CIRCULATIONAHA.117.028213. Epub 2017 Oct 3. PubMed 28974520 ↗
  • Bagdade J, Barter P, Quiroga C, Alaupovic P. Effects of Torcetrapib and Statin Treatment on ApoC-III and Apoprotein-Defined Lipoprotein Subclasses (from the ILLUMINATE Trial). Am J Cardiol. 2017 Jun 1;119(11):1753-1756. doi: 10.1016/j.amjcard.2017.02.049. Epub 2017 Mar 18. PubMed 28431663 ↗
  • Barter PJ, Rye KA, Tardif JC, Waters DD, Boekholdt SM, Breazna A, Kastelein JJ. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation. 2011 Aug 2;124(5):555-62. doi: 10.1161/CIRCULATIONAHA.111.018259. Epub 2011 Jul 18. PubMed 21804130 ↗
  • Dogan S, Duivenvoorden R, Grobbee DE, Kastelein JJ, Shear CL, Evans GW, Visseren FL, Bots ML; Radiance 1 and Radiance 2 Study Groups. Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia. Ann Med. 2010 Sep;42(6):447-64. doi: 10.3109/07853890.2010.499132. PubMed 20645885 ↗
  • Dogan S, Duivenvoorden R, Grobbee DE, Kastelein JJ, Shear CL, Evans GW, Visseren FL, Bots ML; Radiance 1 and 2 Study Groups. Completeness of carotid intima media thickness measurements depends on body composition: the RADIANCE 1 and 2 trials. J Atheroscler Thromb. 2010 May;17(5):526-35. doi: 10.5551/jat.3269. Epub 2010 Mar 13. PubMed 20228610 ↗
  • Vergeer M, Bots ML, van Leuven SI, Basart DC, Sijbrands EJ, Evans GW, Grobbee DE, Visseren FL, Stalenhoef AF, Stroes ES, Kastelein JJ. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation. 2008 Dec 9;118(24):2515-22. doi: 10.1161/CIRCULATIONAHA.108.772665. Epub 2008 Nov 24. Erratum In: Circulation. 2009 Feb 10;119(5):e197. PubMed 19029469 ↗
  • Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007 Nov 22;357(21):2109-22. doi: 10.1056/NEJMoa0706628. Epub 2007 Nov 5. PubMed 17984165 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2004, a primary completion of Jun 2007 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2005
First posted
Aug 24, 2005
Start
Jul 2004
Primary completionActual
Jun 2007
CompletionActual
Jun 2007
Results delay requested
Jan 30, 2012
Last update
Feb 3, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00134264
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 24, 2005
Start date
Jul 2004
Primary completion
Jun 2007
Completion
Jun 2007
Last update
Feb 3, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Torcetrapib · Atorvastatin

Start the discussion